The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.
March 18th 2024
Senators Ron Wyden and Mike Crapo reaffirm their support on 2 health care bills that passed the United States Senate Committee on Finance in 2023.
Biosimilar Adalimumab, Etanercept Have Equivalent Effectiveness to Reference Drugs Over 48 Months
February 9th 2024The levels of disease activity after 6 months of tumor necrosis factor-α inhibitors could help predict the response to therapy at 4 years for those who have long-standing rheumatoid arthritis.
Read More
No Difference Observed Between Branded, Biosimilar Enoxaparin for Post-Operative Thrombosis
January 4th 2024There was no statistically significant difference between Lovenox (Sanofi–Aventis Pharmaceuticals, France) and biosimilar enoxaparin in the occurrence of post-operative thrombosis for digestive cancer.
Read More
Biosimilar Candidate GP40141 Found Similar to Romiplostim for Idiopathic Thrombocytopenic Purpura
December 1st 2023The aim of developing GP40141 as a biosimilar is to help reduce the cost of the drug and make treatment more affordable for those with idiopathic thrombocytopenic purpura, according to investigators.
Read More
Interchangeability Designation Still Widely Debated, Prescribers Hesitant About Biosimilars
October 19th 2023The FDA is the only authority that can designate a biosimilar as interchangeable with its reference product, which requires that the product has similar clinical results for the same indication.
Read More
Study: No Difference Found in Safety of Reference Biologic, Biosimilar
October 9th 2023In the first systematic review using statistical methods, investigators found switching from a reference biologic to a biosimilar was comparable in safety, but no conclusion on immunogenicity could be drawn.
Read More